Edition:
United States

NovaBay Pharmaceuticals Inc (NBY.A)

NBY.A on American Stock Exchange

3.40USD
4:02pm EDT
Change (% chg)

$0.10 (+3.03%)
Prev Close
$3.30
Open
$3.35
Day's High
$3.40
Day's Low
$3.35
Volume
551
Avg. Vol
3,708
52-wk High
$5.05
52-wk Low
$1.95

Latest Key Developments (Source: Significant Developments)

Novabay Pharmaceuticals sees FY 2017 revenue $19 million
Thursday, 23 Mar 2017 04:05pm EDT 

Novabay Pharmaceuticals Inc : Novabay Pharmaceuticals reports 2016 full year and fourth quarter financial results and provides 2017 financial guidance . Q4 sales rose 149 percent to $4.1 million . Q4 loss per share $0.11 . Sees FY 2017 revenue up 60 percent . Sees FY 2017 revenue $19 million . Novabay Pharmaceuticals Inc- Sees 2017 net loss of $6.2 million, excluding effect of non-cash gain on change in fair value of warrant liability .Novabay Pharmaceuticals Inc- Sees 2017 cash burn of $3 million.  Full Article

NovaBay Pharmaceuticals posts Q2 loss per share $0.36
Thursday, 11 Aug 2016 04:05pm EDT 

NovaBay Pharmaceuticals Inc : NovaBay Pharmaceuticals reports 2016 second quarter financial results . Q2 loss per share $0.36 . Q2 sales rose 164 percent to $2.7 million .Says affirms outlook to reach positive cash flow from operations in December 2016.  Full Article

Novabay Pharmaceuticals appoints Mark Sieczkarek president and CEO
Monday, 13 Jun 2016 06:50am EDT 

Novabay Pharmaceuticals Inc : On track to achieve target of positive cash flow from operations by end of 2016 & accelerated revenue growth beyond . Mark Sieczkarek has served as co's interim president and ceo since november 2015 .Novabay pharmaceuticals appoints Mark M. Sieczkarek president and chief executive officer.  Full Article

Novabay Pharmaceuticals files for offering of 581,423 shares of common stock issuable upon exercise of outstanding warrants
Thursday, 9 Jun 2016 05:55pm EDT 

Novabay Pharmaceuticals Inc :Files for offering of 581,423 shares of co's common stock issuable upon exercise of outstanding warrants.  Full Article

Novabay Pharmaceuticals reports Q1 loss per share $1.24
Thursday, 12 May 2016 04:05pm EDT 

Novabay Pharmaceuticals Inc : Says affirms outlook to reach positive cash flow from operations by end of 2016 .Q1 loss per share $1.24.  Full Article

NovaBay Pharmaceuticals Inc announces $2.83 mln private placement
Wednesday, 24 Feb 2016 04:48pm EST 

NovaBay Pharmaceuticals Inc:Announces $2.83 million private placement.Says Novabay chairman and interim president and CEO Mark M. Sieczkarek also participated in the private placement.  Full Article

NovaBay Pharmaceuticals says secured $3 mln bridge loan
Thursday, 7 Jan 2016 07:00am EST 

NovaBay Pharmaceuticals:Says co has secured a $3 million bridge loan.Novabay pharmaceuticals-co has already received approximately $1.66 million, with the remaining approximate $1.37 million to be funded later this month.Says loan has a three-year term with no pre-payment penalty.  Full Article

NovaBay Pharmaceuticals names Chairman Mark M. Sieczkarek Interim President and CEO
Thursday, 19 Nov 2015 06:00am EST 

NovaBay Pharmaceuticals:Says names Chairman Mark M. Sieczkarek Interim President and CEO.Mark M. Sieczkarek Replacing Former President and CEO, Co founder Ron Najafi.  Full Article

NovaBay Pharmaceuticals reschedules third quarter 2015 conference call to November 19
Monday, 16 Nov 2015 06:00am EST 

NovaBay Pharmaceuticals:Says has rescheduled date to report third quarter financial results and hold investment community conference call to November 19.  Full Article

NovaBay pharmaceuticals announces partnership with ALPHAEON to Bring Avenova to Ophthalmologists and Their Patients across the U.S.
Thursday, 24 Sep 2015 07:00am EDT 

NovaBay Pharmaceuticals Inc:Announces that they have formed a partnership that will add NovaBay's breakthrough Avenova((tm)) to the products that ALPHAEON makes available to patients and doctors.  Full Article

More From Around the Web

BRIEF-Novabay Pharmaceuticals sees FY 2017 revenue $19 million

* Novabay Pharmaceuticals reports 2016 full year and fourth quarter financial results and provides 2017 financial guidance